The pharmacokinetics of infliximab has been determined in clinical studies in a variety of indications. In general, maximal or trough serum concentrations of infliximab are proportional to the dose of antibody administered independent of the inflammatory condition of the patient (summarized in Table 2.1). The volume of distribution is independent of the dose and indicates that infliximab is primarily distributed in the vascular space. The terminal half-life of infliximab is 8.0-9.5 days and the antibody is still detectable in the serum 12 weeks after the last infusion (Kavanaugh et al. 2000; Centocor 2006; Cornillie et al. 2001).
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.